CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
INCAGN01949 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03241173
NCT03241173Phase 2Completed
CompareCT.gov

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Incyte Biosciences International Sàrl·interventional·Posted Aug 7, 2017·Updated Sep 27, 2022

In Brief

A Phase 2 clinical trial evaluating INCAGN01949, Nivolumab, and 1 other intervention for Advanced Malignancies. Completed, enrolled 52 participants across 15 sites.

Detailed Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignancies
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 7, 2017
Enrollment StartOct 9, 2017
Primary CompletionSep 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.9 years ago

Interventions

INCAGN01949drug

In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.

Nivolumabdrug

Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Ipilimumabdrug

Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.